Latest Content

Alison Ankiewicz explains how pelvic physical therapy restores tissue, sexual function and emotional confidence for patients after cancer treatment.

Jennie Smythe, a breast cancer survivor, shared her journey from diagnosis to survivorship in an interview with CURE during Breast Cancer Awareness Month.

A diagnosis of esophageal cancer can bring up many questions and concerns. Our goal is to provide you with clear, accurate and educational information.

In September 2025, the FDA approved new treatments for breast, bladder and prostate cancers, plus biosimilars and a subcutaneous immunotherapy option.

Oct. 1, Previvor Day, acknowledges us who carry a hereditary cancer syndrome or genetic mutation that significantly increases our risk of cancer.

Adding Tecentriq to chemoradiation improved quality of life and supported twice-daily radiation for patients with limited-stage small cell lung cancer.

The FDA approved the denosumab biosimilars Enoby and Xtrenbo for patients on hormone therapies for breast or prostate cancer that weaken bones.

Dr. Mary B. Beasley discusses evolving role of pathologists in lung cancer care, highlighting how emerging technologies may shape the future of the field.

Heather Ann Yonker expands on strategies for maintaining food safety in the home, particularly for patients with compromised immune systems due to cancer.

For patients with cancer grappling with nausea or vomiting due to their treatments, a potential side effect remedy may be found in their own hands.

Penn Medicine researchers found two oral drugs eliminated dormant breast cancer cells in most patients, with relapse rates dropping to about 4% after seven years.

Napo Pharmaceuticals applied for orphan drug designation for Mytesi to treat diarrhea in patients with breast cancer and brain metastases on targeted therapy.